THQM Stock Overview
Engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв17.50 |
| 52 Week High | лв17.80 |
| 52 Week Low | лв16.90 |
| Beta | 0.038 |
| 11 Month Change | -0.57% |
| 3 Month Change | 1.16% |
| 1 Year Change | 2.94% |
| 33 Year Change | 25.11% |
| 5 Year Change | 81.78% |
| Change since IPO | 635.46% |
Recent News & Updates
Shareholder Returns
| THQM | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | -0.6% | -3.0% | 0.06% |
| 1Y | 2.9% | 4.3% | 10.2% |
Return vs Industry: THQM matched the BG Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: THQM underperformed the BG Market which returned 10% over the past year.
Price Volatility
| THQM volatility | |
|---|---|
| THQM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in BG Market | 8.2% |
| 10% least volatile stocks in BG Market | 2.6% |
Stable Share Price: THQM's share price has been volatile over the past 3 months compared to the BG market.
Volatility Over Time: Insufficient data to determine THQM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 204 | Biser Georgiev | www.tchaikapharma.com |
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers anaesthetic, anti-inflammatory and anti-rheumatic, antibiotic, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. It also provides nutritional supplements.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
| THQM fundamental statistics | |
|---|---|
| Market cap | лв1.61b |
| Earnings (TTM) | лв3.34m |
| Revenue (TTM) | лв49.85m |
481.3x
P/E Ratio32.2x
P/S RatioIs THQM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THQM income statement (TTM) | |
|---|---|
| Revenue | лв49.85m |
| Cost of Revenue | -лв226.00k |
| Gross Profit | лв50.08m |
| Other Expenses | лв46.74m |
| Earnings | лв3.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.036 |
| Gross Margin | 100.45% |
| Net Profit Margin | 6.70% |
| Debt/Equity Ratio | 8.9% |
How did THQM perform over the long term?
See historical performance and comparison